Tweets

Study of 111 TAKayasu arteritis pts Rx w/ 74 MMF+MTX vs 37 CYC/AZA. Response rates at 28 & 52 weeks were 58.1% and 55.4% in the MMF+MTX group, respectively, higher than 32.4% at both time points in the CYC/AZA group. https://t.co/wqlOLH0VEA https://t.co/nbLvcyYkbn
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

Long-term data from the 48-wk phase 2 SLEek study of upadacitinib +/- a BTK inhibitor elsubrutinib, in SLE pts, showed both arms effective (little added from BTK), @ 1yr, 127 pts maintained efficacy, GC dose and flare rates https://t.co/FbTHCGZ4pQ https://t.co/cATXVHsiXV
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

#APLAR2025 Prof Peter Taylor
RA patients have ⬆️ rates of CKD https://t.co/DZl9qpbLhH
Dr Gurdeep S Dulay @gurdeep_dulay ( View Tweet )
1 month 1 week ago

Systemic Sclerosis–Associated ILD
Watch Alicia Hinze, MD, share personalized strategies for managing Systemic Sclerosis–Associated ILD. Sponsored By: Boehringer Ingelheim
https://t.co/Mxg9P50m7C
#ILD #Scleroderma https://t.co/Cmupl7Dgwl
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

Stay sharp in RA, PsA & SpA care. Get the latest breakthroughs + expert insights at RWCS 2026. Don’t miss 'Year in Review: Rheumatology Advances.' Register now: https://t.co/majEsY4tXK https://t.co/fgGniR1OGk
RWCS @RWCSmtg ( View Tweet )
1 month 1 week ago

Metanalysis of 7 studies (1979-2023) shows RA pts on vegetarian or vegan diets achieved no improvement in disease activity or physical function, but did have a small significant improvement in pain. Insufficient Data on Fatigue. Overall, low certainty https://t.co/jeh6gN5Byg
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

SPRING-SIR Italian registry of systemic sclerosis: 1917 SSc pts, 56% had GI Sx, assoc w/ longer Dz duration, more severe Dz, diffuse SSc, ILD, digital ulcers, telangiectasias, & tobacco. In 211 very early SSc, 41% GI Sxs (most esophageal), w/ puffy fingers, & dyspnea. https://t.co/l2hStwavuu
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

Where are we now—and where are we going in ILD treatment?
📅 September 9 (TONIGHT!)| ⏰ 7PM EST (LIVE)
Rheumatology leaders Drs. Sindhu Johnson, Dr. Anna-Maria Hoffmann-Vold, Dr. Scott Matson, and Dr. Jack Cush will review the latest ACR & EULAR guidelines on interstitial lung https://t.co/E30AirP5WX
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

Obstructive sleep apnea in USA is expected to rise from 34·3% in 2020 to 46·2%, resulting in 76·6 million OSA cases by 2050. By 2050 there will be more males w/ OSA (~46 milliion) than females (30·4 million), but greater growth in females over the next 30 years. https://t.co/6YZvSusTWf
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

Multimorbidity predicts flares in rheumatoid arthritis
A study from Olmstead county and the Mayo Clinic shows that multimorbidity and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates.
https://t.co/yGrvDttcEq https://t.co/45LMtvsFor
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

September to Remember (9.5.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.
https://t.co/dPdweMaJuN https://t.co/aExU5kV26Q
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago

Based on a survey in Japan, resolution of dry mouth was the most important symptom resolution reported by SJD pts.
The JCR CPG for SjD suggests RTX for glandular involvement while BEL for extra-glandular involvements.
#APLAR25 @RheumNow https://t.co/SsUvQIM9Eu
Links:
sheila @RHEUMarampa ( View Tweet )
1 month 1 week ago